Key Takeaways
- Record quarter, messy optics: Net revenue hit a record ₹569 crores, but reported EBITDA was buried under ~₹62 crores of one-time provisions spanning a contaminated batch, pension adjustments, soil reclamation and IT project costs.
- India CRAMS is the swing factor: India CRAMS revenue tripled YoY to ₹160 crores but still runs at an operating loss; management expects a "very smart recovery" in FY23 as EDQM remediation is more or less behind them, and India's historically high margins would lift group profitability materially.
- Carbogen Amcis AG margin compressed by mix, not structure: Q4 margin fell to 14.7% because development-stage projects dominated the mix and carry only ~7% margin on material pass-through; management expects normalization back to 20% as the project mix shifts.
- FY23 is pitched as the normalization year: Top line guided to ~10% growth, but profitability expected to improve "much more than the top line," signaling a return to complete normalcy after a year of one-offs and remediation.
- What to watch next quarter: Whether EDQM re-inspection stays on track for October/November 2022, the pace of India CRAMS revenue ramp toward the ₹250–260 crore target, and whether Carbogen Amcis AG margins begin their promised climb back to 20%.
India CRAMS: The Turnaround Bet
- Revenue ramp is real: Q4 FY22 India CRAMS revenue of ₹48 crores was more than double the ₹23 crores a year ago; full-year revenue tripled to ₹160 crores from ₹53 crores in FY21, driven by operational improvements and the resumption of manufacturing for key customers like Johnson and Mylan (now Viatris).
- But it is still loss-making: India operations posted a Q4 operating loss of ~₹6.5 crores, with fixed costs running on under-utilized capacity at Bavla and Naroda suppressing margins. Full-year operating costs held in the ₹30–35 crore quarterly range, but quarter-over-quarter fluctuations occur.
- FY23 target: India operations total revenue expected closer to ₹400 crores, with the CRAMS component at least ₹250–260 crores, at a blended margin of 25% to 30%. Growth in the year after FY23 is pencilled at 15% to 20% for India operations.
- Efficiency over expansion: Management is prioritizing higher output from the seven existing operational plants by adding equipment and improving processes, rather than bringing four additional plants online. This requires customer and regulatory approvals, so the ramp will be gradual.
- Dahej land returned: The long-term lease at Dahej SEZ was surrendered because the original rationale (a contingency site if Naroda were rezoned as green belt) no longer applies; focus is squarely on optimizing Bavla and Naroda.
Arpit J. Vyas: "the idea is to have a less number of plants but to have a greater output and that of course will not happen in a single shot, that will happen slowly and certainly"
EDQM Remediation & Regulatory Path
- Corrective actions nearly done: 85% to 88% of EDQM-related corrective actions are completed, with CAPAs related to IT and quality IT systems being implemented. The company plans to generate one to two months of data, then invite European authorities for re-inspection.
- Timeline: Best case is an EDQM visit in November 2022; worst case is April 2023. Management states the company will be ready "much before" the visit.
- Broader system upgrades underway: SAP is being implemented across all Carbogen Amcis entities except France (where Microsoft Dynamics 365 is already live), and quality systems are being upgraded across both Carbogen Amcis and India.
Arpit J. Vyas: "we have completed almost 85% to 88% of the EDQM-related corrective actions and we are on track to extend the invitation to the European authorities as early as October or November this year."
Carbogen Amcis: Margin Mix & One-Offs
- AG margin compressed by development mix: Q4 margin fell to 14.7% because the bulk of the quarter's CHF 4.5 crore revenue (CHF 3 crore) was development-stage work (pre-clinical phase I/II), where margins are lower and material component invoicing carries only ~7% margin. Full-year margin of 18.7% was comparable to FY21's 19.1%.
- B.V. margin diluted by cholesterol mix: Full-year margin declined to 30% from 34.5% in FY21 because of a higher sales mix of cholesterol versus higher-margin Vitamin D Analog. As Vitamin D Analog sales increase, margins should return to the 32% to 35% range.
- UK margin slipped modestly: Full-year margin declined to 17.6% from 19% in FY21.
- Power and fuel hit: Russia-Ukraine war-driven spikes in gas and fuel prices impacted Carbogen Amcis B.V. and the UK entity by ~₹8 crores; these costs could not be passed on in Q4 because purchase orders were already booked, but management expects to pass on most of the increase as contracts come up for renegotiation.
- Contaminated batch provision: A CHF 0.25 crore (~₹20 crores) provision was taken for impurities in a customer batch at Carbogen Amcis AG, traced to a defective vendor supply. An insurance claim and supplier claim will be filed, and an attempt will be made to repurify the batch; revenue (at least cost) is expected to be booked in coming quarters as a reversal.
Pascal Villemagne: "They are not losing the confidence with Carbogen Amcis. Quite a contrary, they still count on us to resolve the issue and move forward"
Pipeline, Capex & Balance Sheet
- Pipeline at a record: The project pipeline stood at more than CHF 10 crore by end-March, higher than at the end of FY21. Two to three molecules historically reach market authorization per year from this pipeline, though commercialization timing is entirely in customers' hands.
- Capex run rate sustained: Annual capex is expected to remain in the ₹350–450 crore range for the next few years, with FY23 capex expected similar to FY22. Capital work-in-progress of ₹755 crores, mostly related to capex in France and Switzerland, will be capitalized over the next 12 to 15 months.
- French greenfield injectables: The new facility is expected to be operational in a few months, with incremental revenue starting from the next financial year. Positions are being staffed in advance, creating a temporary cost-revenue gap.
- Net debt near peak: Net debt is expected to peak at ~US$130 million and may come lower than the current US$122 million over the next two to three years.
- Working capital contained: Gross working capital rose ~₹200 crores in FY22, but this was largely offset by a ~₹100 crore increase in customer advances; net working capital was fairly in line with the prior year when advances are netted off, and is not expected to increase substantially from current levels.
Pascal Villemagne: "we have a very-very strong pipeline by the end of March, more than CHF 10 crore of the project into the pipeline, so even much more than when we ended the last year '21."
Cost Structure & Margin Recovery Path
- Employee expenses elevated for future revenue: Employee costs rose over the last 12 months due to recruitment for future projects and FOREX impact (90% of overseas entity employee expenses are translated into INR). Steady recruitment will continue as new projects start, but many FTEs already recruited will yield revenue in future periods.
- Other expenses spiked on one-offs: Q4 other expenses rose to ₹145 crores from a ₹75–85 crore quarterly run rate, driven by the one-time items detailed earlier. Going forward, other expenses are expected to remain elevated at ~₹100 crores quarterly, with management targeting 5% to 6% price increases to pass on incremental costs to customers.
- Group margin ambition: FY23 group EBITDA margin is targeted closer to 24%, with Carbogen Amcis AG specifically targeted at 20%. The internal three-to-five-year group EBITDA margin expectation is 28% to 30%.
- Three-to-five-year revenue CAGR: Group-level revenue CAGR is targeted closer to 12% to 15%, with Carbogen Amcis entities expected to deliver close to ~10% CAGR over three years.
Sanjay S. Majmudar: "I think '22-23 looks like very much a normal year that we should see both in terms of a decent normal growth and a significant improvement in profitability is expected. So, if the top line may grow say just around by 10%-odd, the bottom line or the profitability should improve much more than the top line in the current '22-23 which should signal as a return of complete normalcy."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EDQM re-inspection | Invite European authorities for re-inspection | Best case November 2022, worst case April 2023 |
| Carbogen Amcis AG margin recovery | Return to 20% EBITDA margin as project mix normalizes | Coming quarters |
| Carbogen Amcis B.V. margin recovery | Return to 32%–35% range as Vitamin D Analog sales increase | As mix shifts |
| India CRAMS revenue | Total India revenue closer to ₹400 crores, CRAMS at least ₹250–260 crores | FY23 |
| India blended margin | 25% to 30% on ₹400 crores revenue | FY23 |
| India growth thereafter | 15% to 20% revenue growth | Year after FY23 |
| Group revenue growth | ~10% top-line growth | FY23 |
| Group EBITDA margin | Closer to 24% | FY23 |
| Group long-term EBITDA margin | 28% to 30% | Three to five years |
| Group long-term revenue CAGR | Closer to 12% to 15% | Three to five years |
| Annual capex run rate | ₹350–450 crore range | Next few years |
| CWIP capitalization | ₹755 crores capitalized | Next 12 to 15 months |
| Net debt peak | ~US$130 million, then decline from current US$122 million | Next two to three years |
| French injectables revenue | Incremental revenue from new facility | Start of next financial year |
| Contaminated batch recovery | Revenue (at least cost) booked as reversal; insurance and supplier claims filed | Coming quarters |
| Cost pass-through | 5% to 6% price increases to pass on incremental costs | Ongoing |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Net revenue | ₹569 cr, record quarterly revenue |
| Full-year FY22 revenue | ₹2,140 cr, +12% YoY |
| Adjusted EBITDA | ₹84 cr, 15% of net revenue |
| Full-year FY22 adjusted EBITDA | ₹394 cr, vs ₹274 cr in FY21 |
| Cash profit | ₹70 cr |
| Full-year FY22 cash profit | ₹340 cr, vs ₹254 cr in FY21 |
| Total one-off impact | ₹62.34 cr, including batch impurity provision, pension provision, soil reclamation, power and fuel, IT project costs |
| Carbogen Amcis AG EBITDA margin | 14.7% for Q4; full year 18.7% vs 19.1% in FY21 |
| Carbogen Amcis B.V. EBITDA margin | 29.5% for Q4; full year 30% vs 34.5% in FY21 |
| UK entity EBITDA margin | 13.8% for Q4; full year 17.6% vs 19% in FY21 |
| CRAMS India revenue | ₹48 cr, vs ₹23 cr in Q4 FY21 |
| CRAMS Switzerland, France and China revenue | ₹375 cr, +9.4% YoY |
| CRAMS UK revenue | ₹25 cr, +16.5% YoY |
| Carbogen Amcis B.V. revenue | ₹63 cr, -13% YoY |
| India CRAMS operating loss | ₹6.5 cr |
| Net debt | US$122 million as of March 31, 2022 |
| Capital work-in-progress | ₹755 cr |
| Customer advances outstanding | ₹250 cr as of March 31, 2022, vs ₹150 cr in FY21 |
| Pipeline value | more than CHF 10 crore of projects by end of March |
| Orders in hand yet to start | ~$100 million |
| Group-level FY23 revenue growth expectation | 12% to 15% CAGR over three to five years |
| India operations FY23 revenue expectation | closer to ₹400 cr, with blended margin of 25% to 30% |
| Group-level FY23 EBITDA margin target | closer to 24% |
| Group-level three-to-five-year EBITDA margin expectation | 28% to 30% |
| Annual CAPEX run rate | ₹350–450 cr |
| Peak net debt expected | ~$130 million |